Solid Bio’s SGT-003 Data Show DMD Gene Therapy Efficacy Without Liver Toxicity

Potential Accelerated Approval Filing On Track

 
• By Mandy Jackson
  
Solid Bio engineered a novel construct for SGT-003 to differentiate from other DMD gene therapies (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D